Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogastric junction outflow obstruction.

Journal Information

Full Title: Aliment Pharmacol Ther

Abbreviation: Aliment Pharmacol Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of personal interests : PV: None; MG: None; LM: None; GDC: None; FBS: None; ST: None; MF: None; AB: None; MB: None; VS: None; RP: has received lectures fees from Alfasigma; consulting for Reckitt Benckiser and Sofar. CPG: Consulting for Medtronic, Diversatek, Takeda, Ironwood, Isothrive, Quintiles, and Johnson and Johnson; EVS: has received lecture or consultancy fees from Abbvie, Alfasigma, Amgen, Aurora Pharma, Bristol‐Myers Squibb, EG Stada Group, Fresenius Kabi, Grifols, Janssen, Johnson&Johnson, Innovamedica, Malesci, Medtronic, Merck & Co, Reckitt Benckiser, Sandoz, Shire, SILA, Sofar, Takeda, Unifarco; NdB: Lectures fees from Malesci and Reckitt Benckiser. Open Access Funding provided by Universita degli Studi di Pisa within the CRUI‐CARE Agreement."

Evidence found in paper:

"FUNDING INFORMATION None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025